Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000, C544S324000, C544S325000
Reexamination Certificate
active
11118862
ABSTRACT:
Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 5510332 (1996-04-01), Kogan et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 0 330 506 (1989-08-01), None
patent: 1 454 898 (2004-09-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 00/43372 (2000-07-01), None
patent: WO 01/54690 (2001-08-01), None
patent: WO 02/08203 (2002-01-01), None
patent: WO 03/053926 (2003-07-01), None
patent: WO 03/099809 (2003-12-01), None
patent: WO 05/000244 (2005-01-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York 1996, pp. 451 and 596.
Yusuf-Makagiansar etal., Medical Research Reviews 22(2); 146-167, 2002.
Abraham, W.M., et al. “a4-Integrins Mediate Antigen -induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “The Pathogenesis of Adeoptive Murine Autoimmune Diabetes Requires an Interaction between a4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Baron, J.L., et al. “Surface Expression of a4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177: 57-68 (1993).
Berlin, C., et al., “α4β7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MAdCAM-1”Cell, 74:185-195 (1993).
Briskin, M. J., et al. “Structural Requirements for Mucosal Vascular Addressin Binding to its Lymphocyte Receptor α4β7”J. Immunol., 156:719-726 (1996).
Cardarelli, P.M., et al., Cyclic RGD Peptide Inhibits α4β1 Interaction with Connectiving Segment 1 and Vascular Cell Adhesion MoleculeJ. Biol. Chem., 296:1866818673 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I., et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science. 251: 788-791 (1991).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site.”Cell. 60: 577-584 (1990).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature.” J. Clin. Invest. 93: 405-41(1994).
Ferguson, T.A., et al. “Two integrin-binding peptides abrogate T cell-mediated immune responsein vivo” PNAS, 88:8072-8076 (1991).
Hamann, A., et al. “Role of a4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology. 152: 3283-3292 (1994).
Holzmann, B., et al. “Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-like α chain associated with either of two integrin β chains, one of which is novel”EMBO J., 8:1735-1741 (1989).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japanese J. Cancer Res. 83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells.”British J. Cancer. 68: 862-867 (1993).
Li, H., et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb. 13(2): 197-204 (1993).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes.”J. Immunol. 150(6): 2407-2417 (1993).
Okarhara, H., et al. “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1(VCAM-1) in Tumor Necrosis Factor a Enhancement of Experimental Metastasis.”Can. Res. 54: 3233-3236 (1994).
Osborn, L. “Leukocyte Adhesion to Endothelium in Inflammation.”Cell. 62: 3-6 (1990).
Paavonen, T., et al. “In Vivo Evidence of the Role of a4β1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation.”Int. J. Can. 58: 298 (1994).
Paul, L.C.,et al. “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts.”Transpl. Proceed. 25(1): 813-814 (1993).
Postigo, A.A., et al. “Increased Binding of Synovial T Lumphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1).”J. Clin. Invest. 89: 1445-1452 (1991).
Pretolani, M., et al. “Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways.”J. Exp. Med. 180: 795-805 (1994).
Sasseville, V.G., et al. “Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular. Cell Adhesion Molecule-1/a4β1 Integrin Interactions.”Am. J. Path. 144(1): 27-40 (1994).
Schadendorf, D., et al. “Tumour Progression and Metastatic Behaviour In Vivo Correlates with Integrin Expression on Melanocytic Tumours.” J. Path. 170: 429-434 (1993).
Shroff, H.N., “Small Peptide Inhibitors of α4β7Mediated MAdCAM-1 Adhesion to Lymphocytes”Bioorganic. Med., Chem. Lett., 6:2495-2500 (1996).
Springer, T.A. “Adhesion receptors of the immune system.”Nature. 346: 425-434 (1990).
Vanderslice, P., “A Cyclic Hexapeptide Is a Potent Antagonist of α4Integrins”J. Immunol, 158:1710-1718 (1997).
Van Dinther-Janssen, A.C.H.M., et al. “The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Rheumatoid Synovium.”J. Immunology. 147(12): 4207-4210 (1991).
Van Dinther-Janssen, A.C.H.M., et al. “Role of the CS1 adhesion motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node endothelium.”Annals. Rheumatic Dis. 52: 672-676 (1993).
Vedder, N.B., et al. “Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock.”Surgery. 106: 509-516 (1989).
Yang, et al. “Inhibition of insultitis and prevention of diabetes in nonobese diabetic mice by blocking L-selecting and very late antigen 4 adhesion receptors.”Proc. Natl. Acad. Sci., USA. 90: 10494-10498 (1993).
Yang, et al. “A predominant role of integrin α4in the spontaneous development of autoimmune diabetes in nonobese diabetic mice”PNAS., 91:12604-12608 (1994).
Yednock, T.A., et al. “Prevention of experimental autoimmune encephalomyelitis by antibodies against a4β1 integrin.”Nature356: 63 (1992).
Konradi Andrei W.
Pleiss Michael A.
Semko Christopher
Smith Jenifer L.
Stappenbeck Frank
Balasubramanian Venkataraman
Elan Pharmaceuticals Inc.
LandOfFree
Pyrimidine hydantoin analogues which inhibit leukocyte... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine hydantoin analogues which inhibit leukocyte..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine hydantoin analogues which inhibit leukocyte... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787781